Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 164

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Randomized trial comparing the effects of gliclazide, liraglutide, and metformin on diabetes with non‐alcoholic fatty liver disease: 比较格列齐特、利拉鲁肽和二甲双胍对糖尿病合并非酒精性脂肪肝的影响的随机研究

Feng, Wenhuan, Gao, Caixia, Bi, Yan, Wu, Min, Li, Ping, Shen, Shanmei, Chen, Wei, Yin, Tingting, Zhu, Dalong · 2017 · Journal of Diabetes

Abstract

Background: The aim of the present study was to compare the effects of gliclazide, liraglutide, and metformin in type 2 diabetes mellitus (T2DM) patients with non‐alcoholic fatty liver disease (NAFLD). Methods: Eighty‐seven subjects were randomized to receive liraglutide, metformin, or gliclazide for 24 weeks. Primary outcomes included HbA1c levels, intrahepatic fat (IHF) content, and liver function. Results: Both HbA1c levels and IHF content were reduced after treatment in all three groups. However, HbA1c levels were lower in the liraglutide‐ and metformin‐treated groups than in the gliclazide‐treated group, and reductions in IHF content were greater with liraglutide than with gliclazide. Liraglutide and metformin treatments reduced weight and improved liver function. Changes in IHF content were positively correlated with reductions in serum alanine aminotransferase and triglyceride levels, as well as weight. At 24 weeks, reductions in IHF content were greater in subjects with weight loss ≥5%, changes in waistline ≤0 cm (including decreases in waistline), HbA1c reductions ≥2.5%, and HbA1c levels <6.5%. Conclusions: In T2DM patients with NAFLD, compared with liraglutide and metformin, gliclazide resulted in less improvement in liver function, reductions in IHF content and HbA1c levels, and less weight loss; in addition, slightly better improvements were achieved with liraglutide than with metformin.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/1753-0407.12555

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 27

  1. 10.1002/hep.28431 · DOI · Paper page
  2. 10.2337/dc10-2229 · DOI · Paper page
  3. 10.1038/nrgastro.2013.171 · DOI · Paper page
  4. 10.1001/jama.2013.168118 · DOI · Paper page
  5. 10.6061/clinics/2015(08)06 · DOI
  6. 10.1007/s12328-014-0548-5 · DOI
  7. 10.1371/journal.pone.0076161 · DOI
  8. 10.1210/jc.2012-3093 · DOI · Paper page
  9. 10.1155/2016/4597246 · DOI
  10. 10.1016/j.nut.2013.11.008 · DOI
  11. 10.4161/15548627.2014.984271 · DOI · Paper page
  12. 10.1111/apt.12972 · DOI
  13. 10.1002/dmrr.2713 · DOI
  14. 10.1016/j.jdiacomp.2009.05.004 · DOI
  15. 10.1016/S0140-6736(15)00803-X · DOI · Paper page
  16. 10.2169/internalmedicine.52.8961 · DOI · Paper page
  17. 10.1007/s00592-014-0638-3 · DOI
  18. 10.1016/j.jhep.2009.04.012 · DOI · Paper page
  19. 10.1002/jmri.24289 · DOI
  20. 10.1038/oby.2011.302 · DOI
  21. 10.1111/apt.13521 · DOI
  22. 10.1002/oby.21182 · DOI
  23. 10.1002/dmrr.2470 · DOI
  24. 10.3748/wjg.v22.i10.3023 · DOI
  25. 10.2337/dc16-1017 · DOI
  26. Morita Y, 2005, Nateglinide is useful for nonalcoholic steatohepatitis (NASH) patients with type 2 diabetes, Hepatogastroenterology, 52, 1338
  27. 10.1136/gutjnl-2015-310798 · DOI · Paper page

Cited by

See all 164

Metadata

Authors
Feng, W., Gao, C., Bi, Y., Wu, M., Li, P., Shen, S., Chen, W., Yin, T., & Zhu, D.
Venue
Journal of Diabetes
Publisher
Wiley
Published
2017-05-29
Volume
9
Issue
8
Pages
800-809
ISSN
  • 1753-0393 (ISSN-L)
  • 1753-0407
OpenAlex
W2598765141
Cited by
164
References
6
FWCI
10.58
Type
journal article
Language
en
Open access
closed
Funders
National Natural Science Foundation of China (81370947, 81570736, 81570737)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.